1984 – Bernard Kaufman
Published Magnetic Resonance Imaging of the Pituitary Gland in Radiologic Clinics.
1986 – Glaser and colleagues
Published Magnetic Resonance Imaging of the Pituitary Gland in Clinical Radiology.
Their study included 22 patients with pituitary disease and 17 controls. They demonstrated that MRI could identify large pituitary tumours and assess their parasellar and suprasellar extension.
1981: Gd-DTPA was described as a potential MRI contrast agent.
1983: First human administration took place in Berlin on 10 November.
1984: Carr and colleagues published the initial clinical experience in 20 patients.
1988: Magnevist received FDA approval on 28 June.
Contrast-enhanced MRI improved the localization of pituitary microadenomas.
Current Events
